About HeliosDx and Chattahoochee Labs: Having begun operations in 2015, the company has witnessed profit and exceptional growth each year and is predicting well over 6 million dollars in revenue in 2021. This year we take on our third mass spectrometer, the powerful Absciex 4500, which will allow us to serve the massive needs of our clientele, which has been under strain. With the procurement of a new QuantStudio 12x we now have the ability to test 1500 Covid19 patients per day.
Chattahoochee Labs/HeliosDx Announces the Acquisition of Control of a Public Entity, RushNet Inc. and Has Filed with the State of Colorado
Alpharetta, Georgia--(Newsfile Corp. - March 31, 2021) - Chattahoochee Labs/HeliosDx has taken a major step forward in achieving its goal of robust and profitable expansion as well as adding exceptional value to its shareholders and announces the acquisition of public entity RushNet, Inc (OTC Pink: RSHN). Having enjoyed rapid growth in revenues from 1.7 million dollars in 2018 to 2.6 million dollars in 2019, 4.3 million dollars with an adjusted EBITDA of 1.3 million in 2020, and an expected 6...2021-03-31 8:09 AM ET